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Many strains  of group A,  C, and G  streptococci have been shown to possess 
surface receptors for human IgG (1-6). Receptors for human IgA have not been 
found  on  group  C  and  G  streptococci,  though  a  small  number  of group  A 
streptococci, specifically those of M type 4 and M type 60, do bind IgA (1, 7-9). 
Schalen (9) and others (6, 7) have shown that the receptors for IgG are different 
from  those  for  IgA,  and  that  binding  is  specific for  the  Fc  fragment  of the 
antibody molecules. 
Group B streptococci have also been examined  for their ability to bind  IgG 
and  IgA  (2,  7).  Christensen  and  Kronvall  (2) found that  47%  of the  group  B 
strains  that  they tested were capable of agglutinating  IgG-sensitized  sheep red 
blood cells. In another study, Christensen and Oxelius (7) could not demonstrate 
significant uptake of 125I-iabeled  IgA by any of 14 group B strains tested. 
In this paper we report that a number of group B streptococci are capable of 
binding IgA and that IgA binding is correlated with the presence of a  130,000 
moi wt, detergent-extractable protein, and with a reaction with Ic typing serum. 
The  IgA-binding  protein  has been purified and  we have  demonstrated  that  it 
binds  the  Fc  region  of human  serum  or  secretory  IgA,  but  not  any  other 
immunoglobulin. 
Materials and Methods 
Bacterial  Strains.  All  group A  and  B streptococcal strains  used in  this  study were 
obtained from the Lancefield strain  collection  currently maintained  in our laboratory. 
The group A strains  were grown in Todd-Hewitt medium.  The group B strains  were 
grown to late log phase in 200 ml of chemically defined medium (10), centrifuged, washed 
once in Tris-HCl buffer (0.2 M, pH 7.4), and finally suspended in 3.0 ml of the Tris-HCl 
buffer. Aliquots of 200 #1 of this suspension  were used to test IgG and IgA binding.  All 
strains  were typed as Ia,  Ib, Ic,  II, or III using  the typing sera prepared by Dr.  R. C. 
Lancefield. 
Immunoglobulin  Preparations.  Human  IgG was obtained from Sigma Chemical  Co., 
(St. Louis, MO) and human IgA1 and IgA2 were purified from the sera of patients  with 
IgA monoclonal  gammopathy.  Purified human  myeloma proteins of the  IgG1,  IgG2, 
IgG3,  IgG4,  and  IgA2  subclasses  were donated  by Ms.  F.  Prelli.  Secretory IgA  was 
purified from coiostrum by the method of Cebra and Robbins (11). Immunoglobulins 
were labeled with 125I by the chloramine T method (12), or by using Iodo-Beads obtained 
from Pierce Chemical  Co., Rockford, IL. Fc and Fab fragments of IgA1  were prepared 
by cleaving lgA with gonococcal IgA 1-protease (13). 
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Separation of these two fragments by conventional ion exchange, or molecular sieve 
chromatography is difficult because the two fragments have very similar isoelectric points 
and molecular weights. To separate the Fc and Fab fragments of protease-treated IgA, a 
method using hydrophobic affinity chromatography was developed. The cleaved IgA1 
was mixed with an equal volume of 2 M ammonium sulfate in 0.2 M Tris, pH 7.6, loaded 
onto  a  2.5  ×  5  cm  column  of phenyl-Sepharose  previously  equilibrated  with  1.0  M 
ammonium sulfate in 0.1  M Tris HC1, pH 7.6, and the Fab fragment e]uted. The column 
was washed with 5 column volumes of 0.8 M ammonium sulfate in 0.1  M Tris HCI, pH 
7.6. The Fc fragments were then eluted by washing with 0.1  M Tris HCI, pH 7.6. The 
fractions were characterized by sodium dodecyl sulfate-polyacrylamide gel electrophoresis 
(SDS-PAGE). 1 
Immunoglobulin Binding to Streptococci.  A 200-#1 aliquot of bacteria was mixed with 10 
#1  of l~SI-labeled  immunoglobulin  (300  ng)  and  incubated  at  22°C  for  15  min.  The 
suspension was centrifuged and washed with  1.5  ml of Tris buffer. The percentage of 
IgA bound  to the bacteria was calculated from the  number of counts in  the bacterial 
pellet and those in the supernatant and the wash. Binding inhibition experiments were 
also performed. The various human IgA preparations (60 #g of 7S, 9S, or Fc fragments) 
or  200  ~1  of serum  from  various  "  ~2~  species  of ammal  were  added  to  the  I-labeled 
immunoglobulin before incubation with the bacteria. 
Triton  Extraction  of the  Bacteria.  Overnight  cultures  of bacteria  were  centrifuged, 
washed once in Tris-HCl buffer (pH 7.4, 0.2 M), and resuspended in 0.2% Triton X-100 
in 0.1  M citrate buffer, pH 5.5, 0.1  M NaCI. Triton extraction was allowed to proceed 
for 48 h at 37 °C after which the bacteria were pelleted and the supernatant analyzed by 
SDS-PAGE (14) using a  10% polyacrylamide gel.  Duplicate gels were processed by the 
Western blot method (15) to transfer the proteins onto nitrocellulose sheets. These were 
washed once with  0.1  M Tris-HCl, pH 8.0 containing 0.1  M  NaCI and 0.05%  Brij  35, 
and  incubated  with  5%  bovine serum albumin  before the  addition  of ~25I-IgA. After 
incubation with ~2~I-IgA for 2 h at 37 °C, the nitrocellulose sheets were washed extensively 
(0.15 M NaCI containing 0.05% Brij), dried, and exposed to film. 
Extraction  and Purification  oflgA-binding  Protein.  The Ib strain  H36B5 was used to 
inoculate 60 1 of dialyzed Todd-Hewitt broth (Difco Laboratories, Detroit, MI) supple- 
mented with 3 kg of dextrose and harvested by centrifugation in mid-log phase growth. 
The pelleted bacteria were suspended in 1.5 1  of 2% SDS (Sigma Chemical Co.) in distilled 
water and boiled with stirring for 60 min. The bacteria were removed by centrifugation 
and the proteins in the supernatant precipitated by the addition of 2.5 vol of cold (4°C) 
ethanol. After centrifugation, the pellet was resuspended in 500 ml of 10 mM Tris-HCl, 
pH 8.0 (Tris buffer). Polysaccharides and other contaminants were removed by precipi- 
tation  of  the  proteins  with  trichloroacetic  acid  (10%  wt/voi).  The  supernatant  was 
discarded and the pellet resuspended in  10 mM Tris buffer, pH 8.0 and reprecipitated 
with 2.5 vol of cold ethanol. Finally, the pellet was dissolved in warm, 37 °C, 0.1  M Tris 
buffer, pH 8.0 containing 0.5 M NaCI, 10 mM EDTA, and 2% SDS (Tris-SDS-2%). 
The protein was applied to a 5.3 x  185 cm column of Sepharose 6B (Pharmacia Fine 
Chemicals Piscataway, N  J) previously equilibrated with the 0.1  M Tris buffer containing 
0.5 M NaCl,  10 mM EDTA, and 0.1% SDS (Tris-SDS-0.1%), and chromatographed at a 
flow rate of 60 ml/h at 37 ° C. Fractions (20 ml) were collected and tested for IgA-binding 
activity in the following manner: An aliquot (200 #i) from each fraction was precipitated 
with ethanol, redissolved in 0.1  M Tris-HCl, pH 9.8  (100 #1), and used to sensitize an 
enzyme-linked immunosorbent assay (ELISA) plate (Immulon II; Dynatech Labs,  Inc., 
Alexandria, VA) overnight at 22 o  C. The plates were washed six times with a solution of 
Brij  35  (0.05%)  in  saline  (Brij-NaCl) and  IgA (10  #g/ml  in  phosphate-buffered saline 
(PBS),  0.05% Brij 35) was added for a period of 4 h. The plates were washed again with 
Brij-NaCl before the addition of rabbit anti-human light chain serum (Dako Corporation, 
Santa  Barbara,  CA)  to  which  alkaline-phosphatase  had  been  conjugated  (16).  After 
overnight incubation at 20°C  the plates were washed with Brij-NaCl and the alkaline- 
l Abbreviations used in this paper:  SDS-PAGE, sodium dodecyl sulfate-polyacrylamide gel electro- 
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phosphatase  substrate,  p-nitrophenyl phosphate (Sigma Chemical Co.), added. Fractions 
showing IgA-binding activity were pooled, precipitated with ethanol, dissolved in Tris- 
SDS-2% and rechromatograpbed on a Sephacryl S-400 column (2.5 x  185,  15 ml]h in 
Tris-SDS-0.1%) as previously  described.  Fractions  (10  ml) were collected,  tested, and 
pooled as before. 
Results 
Binding of IgG and IgA to Group B Streptococci.  A  number of strains of type 
la, Ib, Ic, II, and III group B, and type 4 group A streptococci were tested for 
their ability to bind human IgG and IgA. None of the strains tested bound > 10% 
of the ~SI-labeled IgG. We were able to confirm the results of Schalen et al. (8) 
that the majority of group A strains of M type 4 bind human IgA (Fig.  1). We 
found  that  many  of the  Ib  and  Ic  strains  bound  radiolabeled  IgA.  When 
significant binding was defined as > 15%, then 16 of 23 Ib and 5 of 6 Ic exhibited 
IgA binding (Fig.  1). None of 16 type Ia, 5 type II, or 4 type III strains bound 
IgA (results not shown). A number of strains have been found that show positive 
precipitin  reactions with  two different typing sera and  several of these were 
tested. The II x  Ic type is strains with the type II polysaccharide antigen and the 
Ibc protein, whereas II x  Ib strains express antigenic determinants of the type 
II and Ib polysaccharides. The II x  Ic strains, 22RP279,  F393, and 57RP145 
bound 70.3,  13, and 3%, respectively, of the IgA (Fig.  1). The II x  Ib strains, 
F325 and F326, bound 3% of the IgA (data not shown). 
Inhibition of IgA Binding by Bacteria.  To  further define the  nature of the 
binding of IgA, inhibition studies were performed using the Ib strain  H36B-5 
(the strain which bound the most IgA among those tested). Binding of 25 ng of 
100. 
?) 
,e, 
,< 
_m 
5o 
I: 
o 
0-  i 
& 
•  ! 
M4  Ib  Ic  la  Ilxlc 
FIGURE  1.  The binding of 125I-labeled  IgA by different group B strains and a  number of 
125  type M4 group A strains of streptococci. The ordinate is the percentage of 300 ng  I-labeled 
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radiolabeled human IgA to strain H36B-5 (type Ib) was completely inhibited by 
premixing the IgA with 200 #1 of human serum. Binding of intact IgA was also 
completely inhibited by premixing the radiolabeled IgA (300 ng) with 60 ug of 
purified IgA1  or with  60  ug of purified IgA1  Fc fragments. Addition of the 
same amount of cat, mouse, goat, horse, burro, alligator, or grey nurse shark 
serum did not inhibit the binding of human IgA to this strain. 
Analysis of Triton-extractable Proteins by SDS-PAGE.  11  group B strains were 
extracted with Triton X-100 and the proteins separated on duplicate SDS-PAGE 
gels. One gel was stained for protein with Coomassie Blue (Fig. 2 a). The proteins 
in the other gel were transferred to nitrocellulose, and, after washing, the sheet 
was exposed to labeled IgA. The autoradiograph is shown in Fig. 2 b. It can be 
seen in Fig. 2 a that a number of strains revealed two major proteins of ~ 130,000 
mol wt. These were released from IgA-binding strains, but not from nonbinding 
strains (note the two Ia strains in lanes I  and 2, as well as the 2 II ×  Ib strains, 
lanes 8  and 9,  which did not bind IgA).  Furthermore, there appeared to be a 
correlation between the intensity of the  130,000  mol wt protein band and the 
extent of IgA binding listed in the figure legend. The identity of the IgA-binding 
proteins is shown in Fig. 2 b. The major bands labeled were the two proteins of 
~130,000  mol  wt.  In  all  IgA-binding strains,  however, a  number  of smaller 
molecular weight proteins also bound IgA.  It is  likely that these proteins are 
breakdown products of the larger proteins. 
Extraction and Purification of the IgA-binding Protein.  In preliminary attempts 
to purify the  IgA  binding protein  it  was  noted that  the material was readily 
degraded and lost.  When, however, the bacterial pellet from a  mid-log phase 
culture of the group B streptococcal strain, H36B5, was boiled in SDS, a major 
protein of 130,000 mol wt was released without the concomitant release of active 
proteolytic enzymes. Subsequent molecular sieve chromatography of this extract 
in the presence of 0.1% SDS and isolation of the IgA-binding fractions resulted 
in the copurification of this protein with the IgA-binding activity. When SDS 
polyacrylamide gels  of this  preparation  were blotted  onto  nitrocellulose and 
incubated with 125I-IgA, it was found that this major protein was indistinguishable 
from the IgA-binding band (Fig. 3). 
Specificity of the IgA-binding Protein.  To establish the specificity of the purified 
IgA-binding protein,  competition assays with  purified immunoglobulins were 
performed by iodinating pure human myeloma IgA 1 and adding equal or greater 
concentrations of unlabeled immunoglobulin preparations. The results are sum- 
marized in Table I and indicate that serum IgA1  and colostral IgA are highly 
inhibitory.  Using purified gonococcal IgA 1 protease and hydrophobic affinity 
chromatography,  the  Fab  and  Fc  fragments were  isolated,  and  only  the  Fc 
fragment was inhibitory. It was found that commercial preparations of IgG did 
inhibit the binding, but much less effectively than purified IgA (data not shown). 
To determine whether this was due to trace contamination with IgA or to affinity 
by one of the IgG subclasses, we tested purified myeioma proteins representing 
each of the subclasses.  None of these inhibited the IgA binding significantly. 
Human IgM was also noninhibitory. Two preparations of human IgA2 myeloma 
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FmURE  2.  Binding of 12~I-labeled IgA to Western blots of Triton X-100 extracts of strains 
of group  B  streptococci.  Triton extracts  of various strains of group  B  streptococci  were 
subjected to SDS-PAGE and stained with Coomassie Brilliant R (Fig. 2a). Duplicate gels were 
blotted and, after appropriate preparation, were incubated with l~SI-labeled IgA (4 #g/ml), 
washed, and used to expose photographic film (Fig. 2 b). Extracts of strains are as follows: (lane 
1) 090R, (2) D870 (type Ia), (3) A909, (4) F343-3 (type Ic), (5) A670, (6) H36B-5, (7) A943 
(type Ib), (8) F325, (9) F326 (type II x  Ib), (I0) 2ORP279, and (11) F393 (type II × Ic). These 
strains bound 3, 3, 73, 43, 35, 91, 45, 3, 3, 70, and 13% of added radioactivity when tested 
in the manner described for Fig. 1. 1472  GROUP  B  STREPTOCOCCAL IgA-BINDING PROTEIN 
FIGURE 3.  IgA  binding by the  purified IgA-binding protein. The purified IgA-binding 
protein was subjected to SDS-PAGE. (Lanes 1 and 4) 30 #g IgA-BP; (2 and 5) 15 t~g IgA-BP; 
(3 and 6) 1.5 #g IgA-BP. The right half of the gel was stained with Coomassie Blue. The left 
half of the gel was subjected to Western blotting and, after reaction with ~*SI-labeled  IgA and 
washing, was exposed to film. The photograph represents a montage of the Coomassie-stained 
gel and the autoradiograph. 
TABLE  I 
Specificity of lgA-binding protein 
Inhibitor 
Percent inhibition  of binding caused by immuno- 
globulin concentration: 
1 #g/ml  5 ug/ml  25 #g]ml 
IgA1  46.7  67.9  91.3 
IgA1 Fc  56.4  87.7  96.6 
IgA1 Fab  6.7  1.6  -0.7 
Colostral IgA  28.4  56.1  87.1 
IgA2 +  36.4  32.1  36.2 
tgA2 ++  47.6  43.0  61.0 
IgM  11.3  11.5  5.1 
IgG1  1.7  -1.2  -3.3 
IgG2  14.6  6.4  6.4 
IgG3  6.5  4.6  9.8 
IgG4  9.3  10.1  12.9 
The inhibitors were  present at  the  concentrations indicated,  with  the 
concentration of radioactive  IgA constant at 1 t~g]ml. In wells not sensi- 
tized with IgA-binding  protein there was no significant binding of IgA. 
(+), (++) Two purified human IgA2 myeloma proteins. 
Discussion 
The present study describes the presence of a receptor for human IgA on the 
surface of a number of strains of group B streptococci. This is in contrast to the 
work of Christensen and Oxelius (7) who found no significant binding of IgA to 
14 untyped group B streptococcal strains. 
The ability of group  B  streptococci to bind  IgA appears  to be restricted  to 
strains that react with the anti-Ibc serum, namely, 5 Ic and  16 Ib strain, and one 
II  ×  Ic strains.  Strains of the Ia,  II,  III, and II  x  Ib serotypes bound <15% of 
added IgA. Binding of IgA was found to be specific for the Fc fragment of the 
immunoglobulin  molecule,  and  also  appeared  to  be  remarkably  specific  for 
human IgA. 
Fischetti et al. (17) used Triton to extract M protein from the surface of group RUSSELL-JONES, GOTSCHLICH, AND  BLAKE  1473 
A  streptococci.  We  have  used  this procedure  with  group  B  organisms.  SDS- 
PAGE analysis of Triton-extractable proteins revealed a correlation between the 
extent of IgA binding and the presence of two major protein bands of ~130,000 
mol wt.  Blotting of these gels onto nitrocellulose reaffirmed that the  130,000 
mol wt proteins were indeed the IgA-binding proteins. It is noteworthy that the 
IgG-binding protein isolated from group A  streptococci by Havlicek (6) had a 
molecular weight of 100,000,  distinctly smaller than the IgA-binding protein. 
As can be seen from Fig. 2a and b, strain H36B/5, a type Ib strain, which bound 
91%  of the  radiolabeled  IgA,  had  considerably more of the  130,000  mol wt 
proteins and  could bind  more  12Sl-IgA  than  strains  A670  and  A943  (also  Ib 
strains),  which bound only 35 and 45%  of the IgA. Strain A640,  an Ib strain 
that  did  not  bind  IgA,  completely lacked  the  high  molecular weight protein 
(results not shown). 
Reactivity with the Ibc antiserum has previously been shown (18,  19) to be 
due to the presence of at least two antigenically distinct proteins, the alpha and 
the beta determinant.  However,  only half of the strains  reactive with the  Ibc 
antiserum possessed both of these antigens (19). This may explain why 7 of the 
23 type Ib strains tested in this study did not bind IgA. 
We have been able to purify the IgA-binding protein in an active form. Solid 
phase  radioimmunoassays  indicate  that  the  protein  binds  the  Fc  region  of 
monomeric or polymeric IgA, and that it does not bind IgM or any subclass of 
IgG. In competition assays it appears that IgA2 is able to compete with IgA1 for 
the binding protein, but less effectively, suggesting that the affinity of the binding 
with IgA2 may be lower.  The potential of this protein as an immunochemical 
reagent  analogous  to  staphylococcal  protein  A,  but  specific  for  human  IgA, 
deserves exploration. 
While the results of this study do not address the possible role of the  IgA- 
binding protein in the pathogenesis of group B streptococcal disease, Lance  field 
and  coworkers  (20)  have  previously  shown  that  rabbit  antibodies  to  the  Ibc 
proteins are protective in mice. Baltimore et al. (21) have also demonstrated that 
similar antibodies (also raised in rabbits) are capable of eliciting phagocytosis and 
killing of strains carrying the Ibc protein antigen. It is interesting to note that a 
much higher concentration of antibody was required to kill the Ib or Ic strains 
(which bear the IgA-binding protein) than that required to kill type Ia, II, or III 
strains. 
Summary 
A number of group B streptococcal strains of various serotypes, Ia, Ib, Ic, II, 
and III were examined for their ability to bind human IgG and IgA. No strains 
of group B streptococci were found to bind IgG, but many strains possessing the 
Ibc protein  antigen(s)  were  found  to bind a  significant amount  of IgA.  The 
extent of IgA binding correlated with the amount ofa 130,000 tool wt, detergent- 
extractable protein, and reactivity with the Ic typing sera.  Using nitrocellulose 
blots, it was found that the 130,000 tool wt protein bound human IgA. A method 
was developed to purify the protein while retaining its ability  to bind human 
IgA.  Using solid phase radioimmunoassays, it was determined that the protein 1474  GROUP  B STREPTOCOCCAL  IgA-BINDING PROTEIN 
bound to the Fc region of monomeric or polymeric IgA and that it failed to bind 
IgM or any IgG isotype. 
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